Pomegranate flowers contain antioxidants and photochemical reservoirs. They help the diabetes patients in lowering health complications. Not only flowers, seeds and peel also help in lowering health complications. A previous study done in 2011 indicated that the pomegranate flowers along with the diabetes treatment improve brain performance in diabetes patients. Ayurveda and Unani treatments also use pomegranate flowers for the treatment of diabetes.
A number of studies show peanut butter restricts the development of obesity and type 2 diabetes (T2D). Researchers found that BMI has reduced in the children who ate peanut-based snacks and it is a healthy alternative to meat.
Results of 3-year long LEADER trials on Victoza (Liraglutide) manufactured by Novo Nordisk's were presented at the 76th scientific sessions of ADA. Victoza drug has reduced blood glucose levels and weight. Victoza LEADER drug trials show a 22 percent reduction in cardiovascular death (CVD), 22% lower risk for kidney disease and non-fatal stroke by 13 percent compared with the placebo arm. Atherosclerosis leads an individual to heart attacks and stroke and Victoza plays a role in treating it. Novo Nordisk says Victoza is the only approved GLP-1 receptor agonist which reduces all major CV events vs placebo. Dr. John Buse, director of the UNC Diabetes Care Center is the chairman of the LEADER steering Committee. Victoza drug is commercially available in more than 85 countries for the treatment of type 2 diabetes (T2D).
Update on Aug 8, 2017 : The Committee for Medicinal Products for Human Use (CHMP) panel, which authorizes medicines in the European Union (EU), voted positively for using Victoza (Liraglutide) drug, manufactured by Novo Nordisk following LEADER trial results. The CHMP positive opinion was referred to the European Commission for the approval of the proposed drug indication modification on Victoza (Liraglutide) label. Victoza (Liraglutide) drug is the second drug to be recommended for type 2 diabetes patients (T2D) for the treatment of cardiovascular diseases. The SGLT2 inhibitor Jardiance (empagliflozin), a type 2 diabetes (T2D) drug, was the first drug to include cardiovascular risk reduction on its label in the European Union.
EMPA-REG OUTCOME trial was conducted by the lead investigator Dr. Bernard Zinman, director of the Diabetes Center at the Mount Sinai Hospital. In type 2 diabetes (T2D) individuals, cardiovascular risks increase with age. EMPA-REG OUTCOME trial results indicate that the Jardiance (Empagliflozin) reduces the risk of CV death and hospitalization with heart failure in all age groups. The results were showing the effectiveness of the Jardiance and study results were presented in the American Diabetes Association (ADA) 76th Scientific Sessions at New Orleans.
Part of the retina in the eye to read fine details is called macula. Swelling of macula happens due to the high levels of sugar present in the blood vessels. This is the most common problem in the diabetes patients and 7% of the diabetes patients suffer from this problem. The common treatment for this problem is an injection of a drug directly into the eye every 4 to 6 weeks. This treatment is very expensive and only 50% of the patients may get relief. But Professor Alan Stitt (Queen's University) and Dr. Patric Turowski (UCL Institute of Ophthalmology) in collaboration with the GlaxoSmithKline found that Darapladib (in tablet form) has the potential to reduce the vision loss to a wider group of patients with diabetes. Now researchers are planning for a clinical trial with darapladib drug for an alternative treatment to diabetic related blindness.
The Harvard University researchers studied the food habits and the health records of 200,000 health professionals in the US for the past 20 years and concluded that
Random phase 2 study of Invokana (canagliflozin) drug made by the Janssen (a subsidiary of Johnson & Johnson) indicates that invokana drug has lowered mean glucose levels and glycemic variability in type 1 diabetes (T1D) mellitus patients. Amount of time spent within target glucose range too increased. But the results show an increased risk to ketoacidosis. Lack of insulin causes the body to produce excess blood acids and is called ketoacidosis. Ketoacidosis leads to severe kidney injury and the US FDA warns risks associated with Invokana drug.
A study by Dr. Ramon Estruch of the University of Barcelona indicates that nuts and olive oil in Mediterranean diet prevents weight gain and may even reduce body weight. Study results were published in the Lancet Diabetes and Endocrinology.
According to the data presented during the ADA conference in New Orleans, diabetes patients using OneTouch via patch missed fewer insulin dosages and felt less stress and embarrassment compared with multiple daily insulin injections. With the new OneTouch Via patch on demand insulin delivery system, diabetes patients can receive insulin whenever / wherever required by pressing two buttons on the device. The system is a water resistant and can be used for 3 days.
Gestational diabetes (GD) affects the mother during pregnancy. The born baby can be abnormally large babies (known as macrosomia) with the high blood glucose levels. Obesity can amplify gestational diabetes issues. But how the born baby's health is affected if the obese mother loses weight during the pregnancy? Researchers examined 614 pregnant obese women with gestational diabetes with an average age of 31 years. 151 women have lost weight and 463 women have gained weight after the diagnosis of gestational diabetes (GD). The results showed that
Research findings were presented at the 76th Scientific Sessions of ADA at New Orleans, Louisiana.
Canary Health is a Los Angeles based company that provides chronic health management software. Now, Canary Health partnered with Medtronic and Medtronic became reseller and distributor for Canary Health products. They are planning to develop additional solutions based on Medtronic's and Canary Health product range.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.